Sonoma Pharmaceuticals, Inc. - SNOA STOCK NEWS

Sonoma Pharmaceuticals, Inc. (SNOA) announces its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Amy Trombly and CFO Jerry Dvonch will present the company's business overview. Institutional investors can register for the virtual event through the provided link. Sonoma specializes in developing stabilized hypochlorous acid (HOCl) products for various healthcare applications, reducing infections and promoting healing. The company operates globally, distributing products in 54 countries.

Sonoma Pharmaceuticals (SNOA) reported its Q2 2021 financial results, showing revenues of $3.74 million, a 35% decline year-over-year, but a 2% increase from the previous quarter. The net loss improved to $(95,000) from $(1.1 million) in Q1. Gross profit was $1.24 million, a 33% margin, down from 43% a year ago. Operating expenses decreased by 5% year-over-year. The company raised $7.2 million through stock sales to support new product launches. Cash reserves stood at $8.4 million, indicating a strengthened balance sheet.

Sonoma Pharmaceuticals, Inc. (SNOA) and Dyamed Biotech Pte Ltd. announced an expanded partnership in Southeast Asia to enhance the reach of Sonoma's Microcyn® Technology. This partnership will cover Singapore, Malaysia, Indonesia, and Thailand, facilitating the introduction of several products including Dermacyn® for wound care, Ocucyn® for eye care, and Oracyn® for oral care. Dyamed plans new product launches in 2022, highlighting successful hospital usage in Singapore and Malaysia.

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) and its partner MicroSafe Group announced that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for their product, Nanocyn^® Disinfectant and Sanitizer. This product kills common viruses, including SARS-CoV-2 and Norovirus, within 15 seconds, and common bacteria like MRSA and E. coli within 30 seconds. Nanocyn^® is non-toxic and certified for aircraft use. The company aims to expand its international distribution network while promoting its patented Microcyn^® Technology for various healthcare applications.

Sonoma Pharmaceuticals, Inc. (SNOA) has launched three products—Regenacyn Advanced Scar Gel, Ocucyn Eyelid & Eyelash Cleanser, and MucoClyns—on Amazon for consumer purchase. These products utilize Sonoma's patented Microcyn technology and were previously available only through prescriptions. Regenacyn is clinically proven to improve scars, while Ocucyn addresses eyelid hygiene. MucoClyns serves as a personal decontamination solution. This OTC launch aims to enhance product accessibility and broaden consumer reach, reinforcing Sonoma's position in the healthcare market.

Sonoma Pharmaceuticals (Nasdaq: SNOA) has launched two new dental products, OroGenix Oral Hygiene Rinse in the U.S. and Microdacyn® Oral Care in Switzerland. OroGenix is derived from Sonoma's patented Microcyn® technology, designed for dental hygiene, while Microdacyn60® targets oral infections and inflammation. These products aim to provide effective oral health solutions without staining teeth. Sonoma's COO highlighted the advancements in antimicrobial properties and safety of their new offerings, which are set to benefit dental professionals and patients alike.

Sonoma Pharmaceuticals (SNOA) reported Q1 2022 revenues of $3.7 million, down 36% from $5.8 million in Q1 2021, primarily due to reduced sales in Latin America following the termination of its Invekra contract. Gross profit remained stable at 39%. Operating expenses decreased by 19% to $2.4 million, yet the net loss increased 55% to $1.1 million, attributed to previous business unit sales. Despite challenges, the transition to a distribution model aims to improve profitability for its prescription products. As of June 30, 2021, Sonoma held $2.8 million in cash.

Sonoma Pharmaceuticals (SNOA) reported its fiscal year 2021 and Q4 results, showing a total revenue of $2.2 million for the quarter, declining 50% year-over-year, attributed to a $1.6 million drop in U.S. dermatology sales and revenue adjustments. Annual revenue reached $18.6 million, up 4% from the previous year. Sonoma's operating expenses decreased by 49% in Q4, totaling $2.6 million, mainly due to reduced headcount and manufacturing consolidation. However, the net loss widened to $3.6 million for the quarter, a 111% increase. The company continues to focus on strategic partnerships and international expansion.

Sonoma Pharmaceuticals (Nasdaq: SNOA) has entered a five-year agreement with EMC Pharma to exclusively manage, market, and distribute its HOCl-based dermatology and eye care products in the U.S. EMC Pharma will also distribute certain Microcyn-based wound care products in government channels. The partnership aims to reduce Sonoma's overhead from its unprofitable direct sales model while expanding its distribution network. EMC will acquire existing inventory and adhere to minimum purchase requirements to maintain exclusivity.